Reviewer's report

Title: Effects of resveratrol on Th17 cell-related immune responses under tacrolimus-based immunosuppression

Version: 1 Date: 24 Jun 2018

Reviewer: Mohamed Sayed El-Boshy

Reviewer's report:

1. The authors should be mentioned in the introduction the studies on the immunosuppression of tacrolimus on the Th17 derived immune cells are controversial, where there is several studied approve the promise immunosuppression effect of tacrolimus on the Th17 cells. For example


2. The discussion should be restructure, there are many results in the manuscript controversial with other international studies. The authors should be discussing whey there are difference between their own results and other results, for example:

The authors reported that the Tacrolimus not inhibited the expression and level of IL-17, while the Yago et al., 2012 and Jain et al., 2016, reported the Tacrolimus is potent inhibited the production of IL-17


The authors reported that the resveratrol significantly inhibited the expression and level of IFN-γ, while the Jeong et al., 2014 reported the resveratrol is potent induction IFN-γ.

The authors reported that the Tacrolimus not inhibited the expression and level of IL-22, while the Jain et al., 2016, reported the Tacrolimus is potent inhibited Th-17 to produce IL-22, where reduced by 1.92 fold than positive control.


3. Also, The comment of 2nd reviewer: Every full name should be mentioned first and abbreviated form in the brackets. The manuscript should be revised the whole document, for example in the abstract section the authors mentioned:

* expression of mammalian target of rapamycin in the Jurkat cell line. The rapamycin should be replace with Tacrolimus (Tac).

* The authors mentioned in the abstract: cell differentiation to Th17 cells in PBMCs. The sentence should be rewrite: cell differentiation to Th17 cells in Peripheral blood mononuclear cells (PBMC)
Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

No

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable
Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal